DK3478286T3 - Fremgangsmåder til behandling af ovariecancer - Google Patents
Fremgangsmåder til behandling af ovariecancer Download PDFInfo
- Publication number
- DK3478286T3 DK3478286T3 DK17821262.7T DK17821262T DK3478286T3 DK 3478286 T3 DK3478286 T3 DK 3478286T3 DK 17821262 T DK17821262 T DK 17821262T DK 3478286 T3 DK3478286 T3 DK 3478286T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- ovarian cancer
- treating ovarian
- treating
- cancer
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356461P | 2016-06-29 | 2016-06-29 | |
| US201662402427P | 2016-09-30 | 2016-09-30 | |
| US201762470141P | 2017-03-10 | 2017-03-10 | |
| PCT/US2017/040039 WO2018005818A1 (en) | 2016-06-29 | 2017-06-29 | Methods of treating ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3478286T3 true DK3478286T3 (da) | 2024-01-29 |
Family
ID=60787744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17821262.7T DK3478286T3 (da) | 2016-06-29 | 2017-06-29 | Fremgangsmåder til behandling af ovariecancer |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US20180311224A1 (da) |
| EP (2) | EP4302835A3 (da) |
| JP (2) | JP7083760B2 (da) |
| KR (2) | KR102510996B1 (da) |
| CN (1) | CN109640992A (da) |
| AU (1) | AU2017290244B2 (da) |
| BR (1) | BR112018077492A2 (da) |
| CA (1) | CA3029671C (da) |
| DK (1) | DK3478286T3 (da) |
| ES (1) | ES2969816T3 (da) |
| FI (1) | FI3478286T3 (da) |
| HR (1) | HRP20240136T1 (da) |
| HU (1) | HUE064978T2 (da) |
| IL (1) | IL263925B2 (da) |
| LT (1) | LT3478286T (da) |
| MA (1) | MA45563A (da) |
| MX (1) | MX2018016193A (da) |
| NZ (1) | NZ749413A (da) |
| PL (1) | PL3478286T3 (da) |
| PT (1) | PT3478286T (da) |
| RS (1) | RS65180B1 (da) |
| SG (1) | SG11201811564QA (da) |
| SI (1) | SI3478286T1 (da) |
| WO (1) | WO2018005818A1 (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019008859A2 (pt) | 2016-11-01 | 2019-07-09 | Anaptysbio Inc | anticorpos direcionados contra a morte programada 1 (pd-1) |
| CN110062885A (zh) | 2016-11-01 | 2019-07-26 | 安奈普泰斯生物有限公司 | 针对t细胞免疫球蛋白和粘蛋白3（tim-3）的抗体 |
| CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
| AU2018205401A1 (en) | 2017-01-09 | 2019-07-25 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| MX2019011496A (es) * | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| IL270068B (en) | 2017-04-24 | 2022-06-01 | Tesaro Inc | Manufacturing methods of Niraprib |
| AU2018264992A1 (en) * | 2017-05-09 | 2019-12-05 | Merck Sharp & Dohme B.V. | Combination therapies for treating cancer |
| EP3624850A1 (en) | 2017-05-18 | 2020-03-25 | Tesaro, Inc. | Combination therapies for treating cancer |
| AU2018341479B2 (en) | 2017-09-26 | 2022-02-17 | Tesaro, Inc. | Niraparib formulations |
| JP2020536066A (ja) | 2017-09-30 | 2020-12-10 | テサロ， インコーポレイテッド | 癌を治療するための併用療法 |
| MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| AU2019215450A1 (en) * | 2018-02-05 | 2020-08-27 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| US20210023077A1 (en) * | 2018-04-04 | 2021-01-28 | The Wistar Institut of Anatomy and Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor |
| TWI825191B (zh) | 2018-10-03 | 2023-12-11 | 美商提薩羅有限公司 | 尼拉帕尼（niraparib）游離鹼之結晶形 |
| ES2967517T3 (es) | 2018-10-03 | 2024-04-30 | Tesaro Inc | Sales de niraparib |
| US11640859B2 (en) | 2018-10-17 | 2023-05-02 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
| US10395772B1 (en) | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| TW202116316A (zh) * | 2019-07-15 | 2021-05-01 | 美商提薩羅有限公司 | 治療卵巢、輸卵管及腹膜癌之方法 |
| WO2021035224A1 (en) * | 2019-08-22 | 2021-02-25 | Tempus Labs, Inc. | Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data |
| JP2023548110A (ja) * | 2020-10-29 | 2023-11-15 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 卵巣がんの検出及び治療方法 |
| KR20230114557A (ko) | 2022-01-25 | 2023-08-01 | 서울대학교산학협력단 | 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법 |
| WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
| CN115253066A (zh) * | 2022-07-21 | 2022-11-01 | 湖南安泰康成生物科技有限公司 | 卵巢癌治疗***以及卵巢癌治疗的交变电场发生装置 |
| CN116092631A (zh) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | 铁死亡诱导剂与电场联用的肿瘤治疗*** |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58936B1 (sr) | 2007-01-10 | 2019-08-30 | Msd Italia Srl | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
| WO2009064444A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CN106008460B (zh) | 2008-01-08 | 2022-08-12 | 默沙东公司 | 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 |
| DK3327148T3 (da) | 2010-06-18 | 2021-04-12 | Myriad Genetics Inc | Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle |
| AU2011293635B2 (en) | 2010-08-24 | 2015-11-26 | Children's Medical Center Corporation | Methods for predicting anti-cancer response |
| WO2014052550A1 (en) * | 2012-09-27 | 2014-04-03 | Thomas Jefferson University | Use of parp inhibitors to treat breast cancer |
| US20140363521A1 (en) * | 2013-04-05 | 2014-12-11 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| JP6663350B2 (ja) * | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー，インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 |
| US10238630B2 (en) * | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) * | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| CN105384695B (zh) * | 2014-08-22 | 2019-12-20 | 四川海思科制药有限公司 | 嘧啶衍生物及其制备方法和在医药上的应用 |
-
2017
- 2017-06-29 WO PCT/US2017/040039 patent/WO2018005818A1/en active Application Filing
- 2017-06-29 HU HUE17821262A patent/HUE064978T2/hu unknown
- 2017-06-29 PT PT178212627T patent/PT3478286T/pt unknown
- 2017-06-29 MX MX2018016193A patent/MX2018016193A/es unknown
- 2017-06-29 KR KR1020197002633A patent/KR102510996B1/ko active IP Right Grant
- 2017-06-29 SI SI201731481T patent/SI3478286T1/sl unknown
- 2017-06-29 LT LTEPPCT/US2017/040039T patent/LT3478286T/lt unknown
- 2017-06-29 AU AU2017290244A patent/AU2017290244B2/en active Active
- 2017-06-29 JP JP2018568951A patent/JP7083760B2/ja active Active
- 2017-06-29 SG SG11201811564QA patent/SG11201811564QA/en unknown
- 2017-06-29 RS RS20240163A patent/RS65180B1/sr unknown
- 2017-06-29 FI FIEP17821262.7T patent/FI3478286T3/fi active
- 2017-06-29 BR BR112018077492-8A patent/BR112018077492A2/pt unknown
- 2017-06-29 DK DK17821262.7T patent/DK3478286T3/da active
- 2017-06-29 HR HRP20240136TT patent/HRP20240136T1/hr unknown
- 2017-06-29 MA MA045563A patent/MA45563A/fr unknown
- 2017-06-29 NZ NZ749413A patent/NZ749413A/en unknown
- 2017-06-29 CN CN201780051916.1A patent/CN109640992A/zh active Pending
- 2017-06-29 PL PL17821262.7T patent/PL3478286T3/pl unknown
- 2017-06-29 EP EP23211450.4A patent/EP4302835A3/en active Pending
- 2017-06-29 CA CA3029671A patent/CA3029671C/en active Active
- 2017-06-29 ES ES17821262T patent/ES2969816T3/es active Active
- 2017-06-29 EP EP17821262.7A patent/EP3478286B1/en active Active
- 2017-06-29 KR KR1020237008762A patent/KR20230042136A/ko not_active Application Discontinuation
- 2017-06-29 IL IL263925A patent/IL263925B2/en unknown
-
2018
- 2018-05-22 US US15/986,536 patent/US20180311224A1/en active Pending
-
2021
- 2021-12-27 JP JP2021212103A patent/JP2022031478A/ja active Pending
-
2022
- 2022-02-24 US US17/652,443 patent/US20220175752A1/en not_active Abandoned
- 2022-02-24 US US17/652,422 patent/US20220175751A1/en not_active Abandoned
- 2022-02-24 US US17/652,457 patent/US20220395493A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/463,851 patent/US20240058319A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3478286T3 (da) | Fremgangsmåder til behandling af ovariecancer | |
| DK3559265T3 (da) | Fremgangsmåde til behandling af polynukleotider | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
| DK3445767T3 (da) | Makrocykliske mcl1-inhibitorer til behandling af cancer | |
| DK3221359T3 (da) | Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof | |
| DK3468965T3 (da) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3245225T3 (da) | Sammensætninger og fremgangsmåder til behandling og detektering af cancere | |
| DK3374359T3 (da) | Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
| DK2994533T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3261726T3 (da) | Sammensætning til behandling af acne | |
| DK3353177T3 (da) | Tricykliske heterocykler til behandling af cancer | |
| DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom | |
| DK3318115T3 (da) | Maskine til behandling af svinegylle | |
| DK3303616T3 (da) | Fremgangsmåder til prognose af prostatakræft | |
| DK3534709T3 (da) | Substituerede sulfonylamider til bekæmpelse af skadedyr | |
| DK3478284T3 (da) | Forbindelser og sammensætninger til behandling af cancer |